AdvanCell Partners with Lilly to Develop Targeted Alpha Therapies for Cancer
AdvanCell, a clinical-stage radiopharmaceutical company focused on targeted alpha therapies, today revealed an expansion of its strategic collaboration with Eli Lilly and Company. This expanded partnership aims to research and develop innovative cancer treatments.
AdvanCell, a clinical-stage radiopharmaceutical company specializing in targeted alpha therapies, today announced an expanded strategic collaboration with Eli Lilly and Company to accelerate the development of novel cancer treatments. Under this new agreement, both companies will combine their expertise to advance an expanded portfolio of targeted alpha therapies, leveraging AdvanCell’s proprietary Pb-212 production technology and Lilly’s extensive experience in drug development.
AdvanCell has developed a competitive edge through its proprietary Pb-212 production technology, along with its robust infrastructure for radionuclide development. This infrastructure enables the company to rapidly progress novel Pb-212-based radiotherapeutics from the discovery phase into clinical trials, with a particular emphasis on conducting early-stage clinical trials in Australia. AdvanCell’s efficient production and development capabilities position the company as a leader in the targeted alpha therapy space, particularly in the emerging field of Pb-212-based radiopharmaceuticals.
“This collaboration with Lilly represents a major milestone for AdvanCell, positioning us as a leader in the rapidly growing Pb-212 targeted alpha therapy field,” said Andrew Adamovich, CEO of AdvanCell. “By combining our groundbreaking isotope production technology, infrastructure, and expertise with Lilly’s global scale and deep oncology experience, we aim to bring transformative therapies to patients with difficult-to-treat cancers. We’re particularly pleased to extend and deepen our partnership with Lilly.”
Jacob Van Naarden, President of Lilly Oncology, expressed similar enthusiasm about the collaboration, stating, “Partnering with AdvanCell is in line with our ongoing commitment to advancing innovative radiopharmaceuticals. We are excited to explore the potential of Pb-212-based alpha therapies as we continue our efforts to bring impactful treatments to patients battling cancer.”
The collaboration aims to facilitate the development and clinical advancement of a wider array of targeted alpha therapies using Pb-212, a potent radionuclide. The integration of Lilly’s drug candidate programs and its comprehensive expertise in oncology drug development will allow both companies to accelerate the pace of innovation in this field. This partnership will not only enhance the ability to bring new therapies to clinical trials faster but also increase the potential for these treatments to reach patients more efficiently.
Alpha therapies, including those based on Pb-212, have the potential to offer powerful treatment options for cancers that are difficult to treat with traditional methods. These therapies use radiation to precisely target cancer cells, minimizing damage to surrounding healthy tissue. Pb-212 is considered an ideal radionuclide for targeted therapy because of its favorable half-life and the powerful radiation it emits, which has been shown to be effective against solid tumors and metastatic cancers.
The strategic collaboration with Lilly represents a significant step for AdvanCell as it continues to make strides in the rapidly evolving field of targeted alpha therapy. The partnership will help bring new hope to patients suffering from cancer by providing access to advanced therapies that have the potential to offer more effective and less toxic treatment options.
The financial terms of the collaboration were not disclosed, but both companies have expressed strong confidence that the partnership will accelerate the development and commercialization of Pb-212-based targeted alpha therapies. By leveraging Lilly’s global reach and AdvanCell’s cutting-edge technology, the collaboration aims to bring new, transformative treatment options to cancer patients worldwide.
About AdvanCell:
AdvanCell is a leading innovator in the development of targeted alpha therapies for cancer treatment. The company is focused on harnessing the power of targeted alpha-emitting radionuclides to deliver novel and effective treatments for cancer patients. With advanced manufacturing capabilities, cutting-edge science, and extensive clinical development expertise, AdvanCell is committed to improving cancer outcomes globally. Through its strategic collaborations and innovative approach, AdvanCell is at the forefront of the next generation of cancer therapies.
